What are the FDA-recommended oral dosing regimens of ivermectin for onchocerciasis and strongyloidiasis in adults?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Ivermectin is FDA‑approved in oral form to treat both onchocerciasis (river blindness) and intestinal strongyloidiasis, but the labeled dosing differs by indication: the standard onchocerciasis dose is a single oral administration of approximately 150 micrograms per kilogram (mcg/kg) of body weight, while the labeled regimen for nondisseminated strongyloidiasis is a single oral dose of 200 mcg/kg [1] [2] [3]. Both indications typically rely on single‑dose strategies with follow‑up and occasional retreatment or monitoring rather than prolonged daily dosing [2] [4].
1. Onchocerciasis—single, weight‑based microfilaricidal dose
The FDA‑approved Stromectol label and clinical trial evidence support a single oral dose designed to deliver approximately 150 mcg/kg of ivermectin to treat onchocerciasis, with that dose producing large reductions in skin microfilarial counts in randomized studies and serving as the recommended microfilaricidal strategy in labeling [2]. The primary therapeutic goal in onchocerciasis is to eliminate microfilariae rather than kill adult worms, so ivermectin’s 150 mcg/kg single dose is used to rapidly clear circulating and skin microfilariae and reduce transmission, but it does not eliminate adult Onchocerca volvulus, which is why repeated community or individual dosing programs are common in control programs [2] [5].
2. Strongyloidiasis—single 200 mcg/kg dose is the labeled regimen
For nondisseminated intestinal strongyloidiasis due to Strongyloides stercoralis, the FDA‑approved Stromectol labeling and regulatory documents cite clinical studies in which a single 200 mcg/kg oral dose cured between about 64% and 100% of patients, and the label therefore indicates a single 200 mcg/kg dose as the standard regimen for this indication [3] [4]. Authoritative drug references and clinical resources also summarize that a single 200 mcg/kg dose is typically sufficient for immunocompetent adults, while immunocompromised patients may need repeat or longer courses and careful monitoring [2] [6].
3. Safety signals, expected reactions, and monitoring after treatment
Treatment of onchocerciasis is associated with Mazzotti‑type inflammatory reactions caused by dying microfilariae, and the label warns about allergic, ophthalmologic, and systemic reactions that can occur after dosing for onchocerciasis; such reactions are less expected in patients treated for strongyloidiasis but clinicians should remain vigilant [7] [4]. The label and prescribing information advise follow‑up testing—stool examinations to document clearance in strongyloidiasis and clinical/dermatologic and ophthalmologic monitoring after onchocerciasis treatment—because ivermectin does not kill adult Onchocerca and repeat or community dosing programs are often needed for control [3] [2].
4. Where guidance and practice vary and why labels matter
Some clinical summaries (for example, Mayo Clinic entries) may state a usual single dose of 150 mcg/kg or suggest dose ranges and intervals for repeat treatment depending on clinical context, reflecting that trial designs and practical programmatic use have studied both 150 and 200 mcg/kg regimens in various settings; however, the FDA label remains the canonical regulatory reference specifying ≈150 mcg/kg for onchocerciasis and 200 mcg/kg for strongyloidiasis based on the pivotal studies [6] [2] [3]. Public‑health programs, alternative regimens (e.g., moxidectin for onchocerciasis), and immunocompromised patient management may diverge from a straightforward single‑dose approach and require specialist input or programmatic guidance [5].
5. Bottom line for clinicians and programs
The concise, FDA‑anchored dosing takeaways are clear: for adult onchocerciasis, administer a single oral dose to deliver approximately 150 mcg/kg of ivermectin; for nondisseminated intestinal strongyloidiasis in adults, administer a single oral dose of 200 mcg/kg and perform follow‑up testing as indicated, with special consideration for repeat dosing in immunocompromised patients or programmatic control settings [2] [3] [4]. The regulatory labels and clinical reviews cited here (FDA Stromectol labeling and major clinical references) remain the primary sources for these dosing recommendations and for the safety and monitoring considerations that accompany their use [2] [1] [6].